Lorem X RP-PEMF = Next generation PEMF Modalities
Designed the way nature intended, to work with recovery
Macmed uses a RP license
for the development and marketing of RP-PEMF devices and RP-PEMF protocols. RP technology is not an asset of Macmed;
it is proprietary IP belonging to third parties.
Provisional Patents with license
MACMED S.A. de C.V. is authorized to develop and commercialize LOREM X and related RP-PEMF technology.
The underlying RP technology is the subject of pending U.S. provisional patent applications, including Nos. 63/892,943, 64/096,883, and 64/112,840.
63/892,943
Our provisional RP-PEMF patent was filed on October 3, 2025, covering the new Recovery Primed Medical Modality and claiming international priority under the Paris Convention.
The new basic idea described in the provisional patent is the use of long rest intervals between pulses, typically 8 minutes to 72 hours, in different medical modalities, which create specific RP advantages.
The method patent application covers RP-PEMF use for Wellness devices, Medical devices, and TMS devices, as well as other RP medical modalities.
64/096,883
Relates to Recovery Primed stimulation technology for sensitive or slow-recovering biological systems, using controlled stimulation and recovery-compatible timing to guide adaptive RP-PEMF protocol development.
64/112,840
U.S. Provisional Patent Application No. 64/112,840
Protects phenotype-guided Recovery Primed stimulation methods aimed at selected cardiovascular, endothelial, nitric-oxide, inflammatory, allergy/tolerance, and immune-regulatory applications.
